Publicaciones en colaboración con investigadores/as de Hospital Universitario de Canarias (21)

2024

  1. Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice

    Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 12, pp. 1604-1615

2023

  1. Admixture mapping of severe asthma exacerbations in Hispanic/Latino children and youth

    Thorax, Vol. 78, Núm. 3, pp. 233-241

  2. Alpha-1 antitrypsin deficiency and Pi*S and Pi*Z SERPINA1 variants are associated with asthma exacerbations

    Pulmonology

  3. Human genetics influences microbiome composition involved in asthma exacerbations despite inhaled corticosteroid treatment

    Journal of Allergy and Clinical Immunology, Vol. 152, Núm. 3, pp. 799-806.e6

  4. The upper-airway microbiome as a biomarker of asthma exacerbations despite inhaled corticosteroid treatment

    Journal of Allergy and Clinical Immunology, Vol. 151, Núm. 3, pp. 706-715

2022

  1. Multi-ancestry genome-wide association study of asthma exacerbations

    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, Vol. 33, Núm. 6, pp. e13802

  2. Neuroblastoma in Spain: Linking the national clinical database and epidemiological registries – A study by the Joint Action on Rare Cancers

    Cancer Epidemiology, Vol. 78

2020

  1. A multicenter national survey of children with SARS-CoV-2 infection admitted to Spanish Pediatric Intensive Care Units

    Intensive Care Medicine

  2. The genomics and metagenomics of asthma severity (GEMAS) study: Rationale and design

    Journal of Personalized Medicine, Vol. 10, Núm. 3, pp. 1-16

2017

  1. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

  2. MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression

    PLoS ONE, Vol. 11, Núm. 5

2015

  1. Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 104.e1-104.e5

  2. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5

2014

  1. Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions

    PLoS ONE, Vol. 9, Núm. 12

  2. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

  3. Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes

    International Journal of Tuberculosis and Lung Disease, Vol. 18, Núm. 6

2013

  1. Longer follow-up confirms major improvement in outcome in children and adolescents with Philadelphia chromosome acute lymphoblastic leukaemia treated with continuous imatinib and haematopoietic stem cell transplantation. Results from the Spanish Cooperative Study SHOP/ALL-2005

    British Journal of Haematology, Vol. 162, Núm. 3, pp. 419-421

2011

  1. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): Results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005

    British Journal of Haematology, Vol. 154, Núm. 5, pp. 600-611

2009

  1. Delayed diagnosis of HIV infection in a multicenter cohort: Prevalence, risk factors, response to HAART and impact of mortality

    Current HIV Research, Vol. 7, Núm. 2, pp. 224-230